Antonio F. Cruz

Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal.

NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada.

NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada.

Mercal Capital Corp. is a capital pool company, which engages in the identification and evaluation of potential acquisitions or businesses. The company was founded on August 31, 2015 and is headquartered in Ottawa, Canada.

Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal.

Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.